Atlasonc Inc.

About Atlasonc Inc.

Atlasonc is a clinical-stage biopharmaceutical company focused on developing novel therapies for patients with serious and life-threatening diseases. The company's lead product candidate, ATLS-101, is an investigational gene therapy designed to treat a rare genetic disorder. Atlasonc leverages its proprietary gene editing technology to create precise and effective treatments. Their pipeline also includes other gene therapy programs targeting various genetic conditions. The company is committed to advancing scientific innovation and addressing unmet medical needs in the rare disease space, aiming to bring transformative treatments to patients who currently have limited or no therapeutic options. Atlasonc is dedicated to rigorous research and development to achieve its mission.